Aptose says CG"806 kills cancer cells resistant to other FLT3, BTK inhibitors

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Scientists Want to Create Human Cells That Are Resistant to Viruses

First step, virus resistant; next step, cancer......»»

Category: topSource: newsweekMay 2nd, 2018

Precision Therapeutics subsidiary discovers biomarkers for Thyroid Cancer cells

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2019

This Peninsula biotech foresaw deals worth $3 billion. Now it"s lining up a $57 million merger

OncoMed Pharmaceuticals Inc. — whose wide-ranging deals around cancer stem cells once promised to bring in nearly $3 billion — will merge with a London biotech company for $57.4 million, according to terms of the transaction disclosed Wednesday......»»

Category: topSource: bizjournalsDec 5th, 2018

Scientists may have found a way to treat cancer without chemotherapy by replicating our body"s own self-destruct system

jovan vitanovski/Shutterstock Every day, millions of our cells "kill themselves" and are quickly removed from our system, which helps protect us from potentially harmful cells. Cancer cells, on the other hand, can protect themselves from self-destruct.....»»

Category: topSource: businessinsiderNov 23rd, 2018

Penn researchers land $10.7M grant to study CAR-T cell therapy in solid tumors

The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung .....»»

Category: topSource: bizjournalsOct 22nd, 2018

Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer at ESMO 2018

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology). read more.....»»

Category: blogSource: benzingaOct 19th, 2018

Google has created an algorithm for doctors who diagnose breast cancer

Google's artificial intelligence team has developed an algorithm that's like "spell check" for pathologists, the doctors responsible for diagnosing cancer patients through images of their cells......»»

Category: topSource: moneycentralOct 12th, 2018

Loyola gears up to make its own CAR-T cells to battle cancer

Deep within the labyrinth of Loyola University .....»»

Category: topSource: chicagotribuneSep 26th, 2018

This cancer-fighting biotech sped from startup to IPO filing in 10 months

The team that took Kite Pharma from a startup re-engineering a patient's own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie B.....»»

Category: topSource: bizjournalsSep 17th, 2018

Elephants Are Remarkably Resistant to Cancer. Scientists May Have Found the Reason—A ‘Zombie Gene’

Elephants have a way of being averse to human biological breakdowns. An elephant never forgets, the saying goes. Or, at least, as my colleague.....»»

Category: europeSource: fortuneAug 15th, 2018

Experimental treatment uses modified stem cells to fight cancer

Daniel Apodaca is a 25-year-old film student at UCLA. He's also the first patient in a clinical trial that's testing a treatment using genetically modified bone marrow stem cells to fight cancer......»»

Category: videoSource: cnnJul 20th, 2018

Scientists Developing Drug Which Could "Freeze" Cancer Cells, Stop Them from Spreading

Preventing cancer from spreading is essential to saving lives......»»

Category: topSource: newsweekJun 22nd, 2018

Is CRISPR in Touble After New STAT Report?

Shares of CRISPR Therapeutics tumbled after a report was released that gene-edited cells might cause cancer. The implications of this study could be catastrophic for the company seeing as CRISPR is........»»

Category: blogSource: 247wallstJun 11th, 2018

CRISPR Crashes After Study Highlights Potential Cancer Risk From Gene-Editing

Don't mess with mother nature.. or crowded longs! Crispr Therapeutics led gene-editing stocks lower after new studies published by Nature Medicine found that cells whose genomes are edited with the CRISPR-Cas9 technology have the po.....»»

Category: blogSource: zerohedgeJun 11th, 2018

Studies indicate CRISPR edited cells may up cancer risk, STAT reports

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2018

Tea Leaf Nanoparticles Destroy Up to 80 Percent of Lung Cancer Cells

Scientists think these particles might be useful for computers, solar cells and medical applications......»»

Category: topSource: newsweekMay 21st, 2018

Beautiful Images Show Cancer Sweeping Through Blood, Immune Cells Eating Sugar in Real-Time

We can see detailed images of cells in their natural environment, not just on a glass slide......»»

Category: topSource: newsweekApr 23rd, 2018

Fit & Proper: Lifestyle changes that may help prevent cancer

Cancer cells thrive in acidic environments. It promotes tumor growth and is a breeding ground for almost all viruses, pathogens and bacteria.....»»

Category: topSource: business-standardApr 21st, 2018

Immune therapy doubles lung cancer survival rate

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Category: topSource: bizjournalsApr 17th, 2018

Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy

Loxo Oncology Inc (NASDAQ: LOXO) holds an opportunity to differentiate itself among RET inhibitors while developing medicines for patients with genetically defined cancers, according to Morgan Stanley.  Latest Ratings for LO.....»»

Category: blogSource: benzingaApr 16th, 2018